Immunoglobulin Levels and B-Cell Depletion (1)
B-cell depleting therapies such as Ocrelizumab (Ocrevus), Ofatumumab (Kesimpta) or the newly approved Inebilizumab (Uplizna) for the treatment of NMOSD are currently very important tools for controlling active MS courses and for preventing relapses in
Continue reading





